A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results.
暂无分享,去创建一个
G W Torrance | P Tugwell | P. Tugwell | C. Goldsmith | N. Bellamy | G. Torrance | J. Raynauld | N Bellamy | J-P Raynauld | C H Goldsmith | P. Band | V. Walker | M. Schultz | P A Band | V Walker | M Schultz
[1] G. Singh,et al. NSAID induced gastrointestinal complications: the ARAMIS perspective--1997. Arthritis, Rheumatism, and Aging Medical Information System. , 1998, The Journal of rheumatology. Supplement.
[2] Carol A. Trujillo,et al. The MOS 36-Item Short Form Health Survey: reliability, validity, and preliminary findings in schizophrenic outpatients. , 1998, Medical care.
[3] T O Jefferson,et al. Guidelines for authors and peer reviewers of economic submissions to the BMJ , 1996, BMJ.
[4] P Tugwell,et al. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. , 1993, The Journal of rheumatology.
[5] M. Gold,et al. Panel on cost-effectiveness in health and medicine. , 1996, Medical care.
[6] Thomas J. Schnitzer,et al. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update , 2000 .
[7] C. Helmick,et al. Arthritis and other rheumatic conditions: who is affected now, who will be affected later? National Arthritis Data Workgroup. , 1995, Arthritis care and research : the official journal of the Arthritis Health Professions Association.
[8] D. Rubin,et al. Statistical Analysis with Missing Data. , 1989 .
[9] G. Slama,et al. PHT7: THE FRENCH HEALTH UTILITIES INDEX MARK 3 , 2000 .
[10] R H Brook,et al. Costs attributable to osteoarthritis. , 1998, The Journal of rheumatology.
[11] A. Laupacis,et al. Costs of elective total hip arthroplasty during the first year. Cemented versus noncemented. , 1994, The Journal of arthroplasty.
[12] B. O'brien,et al. A tale of two (or more) cities: geographic transferability of pharmacoeconomic data. , 1997, The American journal of managed care.
[13] A S Detsky,et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[14] Milton C. Weinstein,et al. Recommendations for Reporting Cost-effectiveness Analyses , 1996 .
[15] M C Weinstein,et al. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. , 1996, JAMA.
[16] A Osteo-Artrite do Joelho (Osteo-Arthritis of the Knee) , 1958 .
[17] J. Kellgren,et al. Osteo-arthrosis and Disk Degeneration in an Urban Population * , 1958, Annals of the rheumatic diseases.
[18] C. Sherbourne,et al. The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .
[19] E. Balazs,et al. Viscosupplementation: a new concept in the treatment of osteoarthritis. , 1993, The Journal of rheumatology. Supplement.
[20] T. Schnitzer,et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. , 1995, Arthritis and rheumatism.
[21] H. Sintonen,et al. Comparison of Finnish and U.S.-based Visual Analog Scale Valuations of the EQ-5D Measure , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.
[22] C. Goldsmith,et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. , 1988, The Journal of rheumatology.
[23] E. Yelin,et al. The economic impact of the rheumatic diseases in the United States. , 1989, The Journal of rheumatology.
[24] M. Cross,et al. Outcomes after hip or knee replacement surgery for osteoarthritis , 1999, The Medical journal of Australia.
[25] N. Bellamy,et al. A comparative study of telephone versus onsite completion of the WOMAC 3.0 osteoarthritis index. , 2002, The Journal of rheumatology.
[26] M. Drummond,et al. Cost-effectiveness league tables: more harm than good? , 1993, Social science & medicine.
[27] W. Olszynski,et al. Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. , 1996, The Journal of rheumatology.
[28] K. Brøsen,et al. CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus , 1999, Annals of the rheumatic diseases.
[29] D Menon,et al. Canadian Coordinating Office for Health Technology Assessment. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[30] M. Weinstein,et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. , 1996, JAMA.
[31] C. Bell,et al. A Comprehensive League Table of Cost-Utility Ratios and a Sub-table of "Panel-worthy" Studies , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.
[32] C. Bombardier,et al. Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies? , 1999, Annals of the rheumatic diseases.
[33] J. Neumann,et al. Theory of games and economic behavior , 1945, 100 Years of Math Milestones.
[34] M. Hochberg,et al. A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the knee, with an emphasis on trial methodology. , 1997, Seminars in arthritis and rheumatism.
[35] D. Felson. The epidemiology of knee osteoarthritis: results from the Framingham Osteoarthritis Study. , 1990, Seminars in arthritis and rheumatism.
[36] T. Schnitzer,et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. , 1995, Arthritis and rheumatism.